• 1039 Citations
  • 17 h-Index
1975 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Yutaka Hattori is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Thalidomide Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Fibroblast Growth Factor Receptors Medicine & Life Sciences
Angiogenesis Inhibitors Medicine & Life Sciences
Genes Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Intercellular Signaling Peptides and Proteins Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1975 2019

  • 1039 Citations
  • 17 h-Index
  • 64 Article
Cell Separation
Hydrogel
Hydrogels
Silicon Dioxide
beads

A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress

Okayama, M., Kitabatake, S., Sato, M., Fujimori, K., Ichikawa, D., Matsushita, M., Suto, Y., Iwasaki, G., Yamada, T., Kiuchi, F., Hirao, M., Kunieda, H., Osada, M., Okamoto, S. & Hattori, Y., 2018 Nov 2, In : Biochemical and Biophysical Research Communications. 505, 3, p. 787-793 7 p.

Research output: Contribution to journalArticle

Endoplasmic Reticulum Stress
Biological Products
Multiple Myeloma
Apoptosis
Oxygen

A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest

Aida, S., Hozumi, M., Ichikawa, D., Iida, K., Yonemura, Y., Tabata, N., Yamada, T., Matsushita, M., Sugai, T., Yanagawa, H. & Hattori, Y., 2017, (Accepted/In press) In : Biochemical and Biophysical Research Communications.

Research output: Contribution to journalArticle

G2 Phase Cell Cycle Checkpoints
Pharmacokinetics
Multiple Myeloma
Polyethylene glycols
Cells
1 Citation (Scopus)

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients

Matsushita, M., Ozawa, K., Suzuki, T., Nakamura, M., Nakano, N., Kanchi, S., Ichikawa, D., Matsuki, E., Sakurai, M., Karigane, D., Kasahara, H., Tsukamoto, N., Shimizu, T., Mori, T., Nakajima, H., Okamoto, S., Kawakami, Y. & Hattori, Y., 2017 Sep 1, In : Blood Cancer Journal. 7, 9, e601.

Research output: Contribution to journalArticle

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Stem Cells
Therapeutics
T-Lymphocytes
2 Citations (Scopus)

Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma

Suto, Y., Sato, M., Fujimori, K., Kitabatake, S., Okayama, M., Ichikawa, D., Matsushita, M., Yamagiwa, N., Iwasaki, G., Kiuchi, F. & Hattori, Y., 2017 Oct 1, In : Bioorganic and Medicinal Chemistry Letters. 27, 19, p. 4558-4563 6 p.

Research output: Contribution to journalArticle

Lead compounds
Biological Products
Multiple Myeloma
Pharmaceutical Preparations
Proteasome Inhibitors